# Abbreviated 510(k) Summary for the Beckman Coulter UniCel® DxH 800 COULTER® Cellular Analysis System

1.0 Submitted By:

Eric Grace   
Senior Staff, Product Management   
Beckman Coulter, Inc.   
11800 SW 147th Avenue, M/C: 31-B06 Miami, Florida 33196-2500   
Telephone: (305) 380-2728   
FAX: (305) 380-3618

# 2.0 Date Submitted:

March 13th, 2012

# 3.0 Device Name and Classification

Proprietary Name: UniCel $\textcircled{8}$ DxH 800 COULTER $\textsuperscript { \textregistered }$ Cellular Analysis System

Classification Number: 21 CFR $\ S$ 864.5220 - Automated differential cell counter

Classification: Class II

Product Code: GKZ

Panel: Hematology

4.0 Predicate Device:

<table><tr><td rowspan=1 colspan=1>Predicate Product</td><td rowspan=1 colspan=1>510(K)Number</td><td rowspan=1 colspan=1>DateCleared</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>21 CFR</td><td rowspan=1 colspan=1>ProductCode</td></tr><tr><td rowspan=1 colspan=1>UniCel® DxH 800COULTER®Cellular AnalysisSystem</td><td rowspan=1 colspan=1>K081930•</td><td rowspan=1 colspan=1>12/19/2008</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>864.5220</td><td rowspan=1 colspan=1>GKZ</td></tr></table>

The updated $\mathrm { D x H 8 0 0 }$ system uses the same reagents, controls and calibrators as the cleared device; there are no changes to these products as a result of the changes prompting this submission of the $\boldsymbol { \mathrm { D x H 8 0 0 } }$ .

# UniCel® DxH 800 COULTER® Cellular Analysis System Update $5 1 0 ( \mathbf { k } )$ submission Section 5: 510(k) Summary - Updated

The updated $\mathrm { D x H } 8 0 0$ sm picple eation, agent, contls n clators  egal c device.

The UniCel® DxH 800 COULTER $^ \mathrm { \textregistered }$ Cellular Analysis System $\mathrm { ( D x H 8 0 0 ) }$ is intended for In Vitro Diagnostic Use in clinical laboratories. The $\mathrm { D x H } 8 0 0$ System provides automated complete blood count, leukocyte differential, nucleated red blood cell (NRBC) enumeration and reticulocyte analysis as well as an automated method for enumeration of the Total Nucleated Cells (TNC) and Red Blood Cells (RBC) in body fluids.

The $\mathrm { D x H } 8 0 0$ System is intended to separate patients with normal hematological parameters from patients who need additional studies of any of these parameters. These studies might include further measurements of cell size and platelet distribution, manual WBC differential or any other definitive test that helps diagnose the patient's condition.

The $\mathrm { D x H } 8 0 0$ system is comprised of the analyzer (see Figure 1 and Table 1), an optional and  urTabl u ll , qualy and calibration reagents, and reagents for system cleaning (see Table 3).

![](images/4f26eeb43404b049dddae0af61aee55495786171de12783db8d8a00fc3fa2621.jpg)  
Figure 1: Bench top DxH 800 System

Table 1: Description of $ { \mathbf { D } }  { \mathbf { x } }  { \mathrm { H } } \ 8 0 0$ components   

<table><tr><td rowspan=1 colspan=1>Figure 1 #</td><td rowspan=1 colspan=1>System Components</td><td rowspan=1 colspan=1>Description / Function</td></tr><tr><td rowspan=1 colspan=1>Item 1</td><td rowspan=1 colspan=1>Specimen Processing Module(SPM)</td><td rowspan=1 colspan=1>Process specimens — providesfunctionality for specimen transport,specimen identification and specimenmixing. Mixed specimens are sampledand required volumes of specimen aremixed and incubated with applicablereagents. The prepared specimen/reagentmix is presented to applicable analyticalmodules where the analysis and raw datageneration occurs. Raw data is sent toSystem Manager for analysis.</td></tr><tr><td rowspan=1 colspan=1>Item 2</td><td rowspan=1 colspan=1>System Manager</td><td rowspan=1 colspan=1>Personal Computer (PC) basedworkstation running system applicationspecific software  Provides systemcontrol functions for the SPM. Receivesraw data from SPM and performsanalysis to generate applicable parameterresults. Provides data management andstorage, provides test order management,results review and reporting, qualitycontrol functionality, diagnostics andmaintenance procedures. User interactionis provided via touch screen, keyboardand mouse. Connects with laboratoryinformation systems (LIS).</td></tr><tr><td rowspan=1 colspan=1>Item 3</td><td rowspan=1 colspan=1>Hand held Barcode scanner</td><td rowspan=1 colspan=1>Provides user the capability for manualsample identification and entry ofbarcoded reagent information for reagenttracking</td></tr><tr><td rowspan=1 colspan=1>Item 4</td><td rowspan=1 colspan=1>Pneumatic Supply Module(PSM)</td><td rowspan=1 colspan=1>Supplies vacuum and pressure to theSPM for system operation</td></tr></table>

![](images/c677a5d17d90b78f419d3609c6bd4418b05db4eeb037ea5b89842f5a8e310637.jpg)  
Figure 2: DxH 800 System and Floor stand

Table 2: DxH 800 Floor stand   

<table><tr><td rowspan=1 colspan=1>Figure 2 #</td><td rowspan=1 colspan=1>System Components</td><td rowspan=1 colspan=1>Description / Function</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Floor Stand (Optional)</td><td rowspan=1 colspan=1>Provides self-contained support for theSPM as well as easy access storage forreagents and waste containers.Additionally, the Floor Stand houses thePneumatic Supply module on anintegrated pull-out shelf.</td></tr><tr><td rowspan=1 colspan=1>Item 1</td><td rowspan=1 colspan=1>Reagent Drawer</td><td rowspan=1 colspan=1>Provides storage and SPM supply tubingfor connection of two 10L Diluentcontainers</td></tr><tr><td rowspan=1 colspan=1>Item 2</td><td rowspan=1 colspan=1>Waste Drawer</td><td rowspan=1 colspan=1>Provides storage and SPM supply tubingfor connection of two 10L wastecontainers</td></tr><tr><td rowspan=1 colspan=1>Item 3</td><td rowspan=1 colspan=1>Reagent Drawer</td><td rowspan=1 colspan=1>Provides storage and SPM supply tubingfor connection of Cell Lyse, Diff Pack,Retic Pack and Cleaner reagents</td></tr><tr><td rowspan=1 colspan=1>Item 4</td><td rowspan=1 colspan=1>Pneumatic Supply Module</td><td rowspan=1 colspan=1>Provides storage and pressure vacuumsupply connections for SPM</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Analytical Reagents:</td><td rowspan=1 colspan=1>Description / Function</td></tr><tr><td rowspan=1 colspan=1>COULTER® DxHDiluent</td><td rowspan=1 colspan=1>A cyanide-free, isotonic buffered saline solution, used to dilute thespecimen prior to analysis. Used for rinsing the Sample ProcessingModule (SPM) components between sample analyses.</td></tr><tr><td rowspan=1 colspan=1>COULTER® DxH CellLyse</td><td rowspan=1 colspan=1>A cyanide-free lytic reagent that lyses red blood cells to allowenumeration and sizing of white blood.cell cells.Works in conjunction with COULTER DxH Diluent to generate astable hemoglobin measurement.Used to discriminate nucleated red blood cells from white bloodcells</td></tr><tr><td rowspan=1 colspan=1>The COULTER® DxHDiff Pack</td><td rowspan=1 colspan=1>The Pack contains two reagents; a cell lytic reagent and a cellpreservative reagent. The lytic reagent is a cyanide-free reagentthat dilutes the blood sample, and lyses red blood cells to allowWBC differentiation. The preservative reagent neutralizes the lyticreagent and preserves the white blood cells for measurement in theflow cell. Together, they provide the five-part differential utilizingthe VCSn technology.</td></tr><tr><td rowspan=1 colspan=1>COULTER® DxH ReticPack</td><td rowspan=1 colspan=1>The pack contains a reticulocyte stain reagent and a reticulocyte-clearing reagent. The reticulocyte stain reagent is a cyanide-freereagent that uses a dye to stain reticulocytes. The reticulocyte-clearing reagent is a cyanide-free reagent that stabilizes the dye-reticulum complex to enhance discrimination of reticulocytes frommature red blood cells utilizing the VCSn technology.</td></tr><tr><td rowspan=1 colspan=1>COULTER® DxHCleaner</td><td rowspan=1 colspan=1>A cyanide-free, aldehyde-free cleaning agent that degradesresidual materials so that they may be flushed from the systemwith the diluent.</td></tr><tr><td rowspan=1 colspan=1>Controls</td><td rowspan=1 colspan=1>Description / Function</td></tr><tr><td rowspan=1 colspan=1>COULTER® 6C CellControl</td><td rowspan=1 colspan=1>An integrated control that enables monitoring of systemperformance for all directly measured and calculated CBC, Diffand NRBC parameters.</td></tr><tr><td rowspan=1 colspan=1>COULTER® Retic-XCell Control</td><td rowspan=1 colspan=1>A control product for monitoring system performance of thereticulocyte parameters.</td></tr><tr><td rowspan=1 colspan=1>COULTER® LIN-XLinearity Control</td><td rowspan=1 colspan=1>A control product for the verification of the reportable range, andcalibration assessment of the WBC, RBC, HGB, and PLTparameters.</td></tr><tr><td rowspan=1 colspan=1>COULTER® BodyFluid Control</td><td rowspan=1 colspan=1>A control product for monitoring system performance of the bodyfluid cycle&#x27;s RBC and TNC count parameters. Additionally,COULTER Body Fluid Control can be used for verification of themeasuring range of the TNC and RBC parameters in the bodyfluid panel.</td></tr><tr><td rowspan=1 colspan=1>COULTERLATRONTM CP-XControl</td><td rowspan=1 colspan=1>A control product used to monitor the volume, conductivity andlight scatter parameter measurements.</td></tr><tr><td rowspan=1 colspan=1>Calibrators</td><td rowspan=1 colspan=1>Description / Function</td></tr><tr><td rowspan=1 colspan=1>COULTER® S-CALCalibrator</td><td rowspan=1 colspan=1>Calibrator for determining calibration factors to ensure accuratemeasurements of directly measured CBC parameters. Assignedassay values are traceable to reference methods.</td></tr></table>

Table 3: DxH 800 Analytical reagent, controls and calibrator

# UniCel® DxH 800 COULTER® Cellular Analysis System Update 510(k) submission Section 5: 510(k) Summary - Updated

# Parameters

The system has the capability to determine the hematologic parameters shown in Table 4.

<table><tr><td rowspan=1 colspan=1>WBC</td><td rowspan=1 colspan=1>White Blood Cell count</td></tr><tr><td rowspan=1 colspan=1>RBC</td><td rowspan=1 colspan=1>Red Blood Cell count (for Whole Blood and Body Fluids)</td></tr><tr><td rowspan=1 colspan=1>HGB</td><td rowspan=1 colspan=1>Hemoglobin</td></tr><tr><td rowspan=1 colspan=1>HCT</td><td rowspan=1 colspan=1>Hematocrit</td></tr><tr><td rowspan=1 colspan=1>MCV</td><td rowspan=1 colspan=1>Mean Corpuscular Volume</td></tr><tr><td rowspan=1 colspan=1>MCH</td><td rowspan=1 colspan=1>Mean Corpuscular Hemoglobin</td></tr><tr><td rowspan=1 colspan=1>MCHC</td><td rowspan=1 colspan=1>Mean Corpuscular Hemoglobin Concentration</td></tr><tr><td rowspan=1 colspan=1>RDW</td><td rowspan=1 colspan=1>Red Cell Distribution Width</td></tr><tr><td rowspan=1 colspan=1>RDW-SD</td><td rowspan=1 colspan=1>Red Cell Distribution Width Standard Deviation (SD)</td></tr><tr><td rowspan=1 colspan=1>PLT</td><td rowspan=1 colspan=1>Platelet count</td></tr><tr><td rowspan=1 colspan=1>MPV</td><td rowspan=1 colspan=1>Mean Platelet Volume</td></tr><tr><td rowspan=1 colspan=1>NE</td><td rowspan=1 colspan=1>Neutrophil percent</td></tr><tr><td rowspan=1 colspan=1>LY</td><td rowspan=1 colspan=1>Lymphocyte percent</td></tr><tr><td rowspan=1 colspan=1>MO</td><td rowspan=1 colspan=1>Monocyte percent</td></tr><tr><td rowspan=1 colspan=1>EO</td><td rowspan=1 colspan=1>Eosinophil percent</td></tr><tr><td rowspan=1 colspan=1>BA</td><td rowspan=1 colspan=1>Basophil percent</td></tr><tr><td rowspan=1 colspan=1>NE#</td><td rowspan=1 colspan=1>Neutrophil absolute number</td></tr><tr><td rowspan=1 colspan=1>LY#</td><td rowspan=1 colspan=1>Lymphocyte absolute number</td></tr><tr><td rowspan=1 colspan=1>MO#</td><td rowspan=1 colspan=1>Monocyte absolute number</td></tr><tr><td rowspan=1 colspan=1>EO#</td><td rowspan=1 colspan=1>Eosinophil absolute number</td></tr><tr><td rowspan=1 colspan=1>BA#</td><td rowspan=1 colspan=1>Basophil absolute number</td></tr><tr><td rowspan=1 colspan=1>NRBC</td><td rowspan=1 colspan=1>Nucleated Red Blood Cell percent</td></tr><tr><td rowspan=1 colspan=1>NRBC#</td><td rowspan=1 colspan=1>Nucleated Red Blood Cell absolute number</td></tr><tr><td rowspan=1 colspan=1>RET</td><td rowspan=1 colspan=1>Reticulocyte percent</td></tr><tr><td rowspan=1 colspan=1>RET#</td><td rowspan=1 colspan=1>Reticulocyte absolute number</td></tr><tr><td rowspan=1 colspan=1>MRV</td><td rowspan=1 colspan=1>Mean Reticulocyte Volume</td></tr><tr><td rowspan=1 colspan=1>IRF</td><td rowspan=1 colspan=1>Immature Reticulocyte Fraction</td></tr><tr><td rowspan=1 colspan=1>TNC</td><td rowspan=1 colspan=1>Total Nucleated Cell (Body Fluids)</td></tr></table>

Table 4: DxH 800 parameters

# Recommended anticoagulants

Whole blood and pre-diluted anti-coagulated blood EPY $\mathbf { K } _ { 2 }$ or $\mathrm { K } _ { 3 }$ - EDTA Serous fluids $\mathbf { K } _ { 2 }$ or $\mathbf { K } _ { 3 }$ - EDTA Synovial fluids (pretreated with Hyaluronidase) EPY ${ \bf K } _ { 2 }$ or $\mathbf { K } _ { 3 }$ - EDTA or heparin

# Specimen Processing Methods

UniCel® DxH 800 COULTER® Cellular Analysis System Update   
510(k) submission   
Section 5: 510(k) Summary - Updated

The DxH 800 provides the user with the ability to obtain a variety of combinations of parameter results through the use of analytical test panels. In addition the specimen analysis can occur via a number of sampling methods on the analyzer.

The test panels and the parameters reported, along with the sampling method that are available to the user are shown in Table 5.

<table><tr><td rowspan=1 colspan=1>Test Panel</td><td rowspan=1 colspan=1>Reported Parameters</td><td rowspan=1 colspan=1>Specimentype</td><td rowspan=1 colspan=1>Sampling Method</td></tr><tr><td rowspan=1 colspan=1>CompleteBlood Count(CBC)</td><td rowspan=1 colspan=1>•   WBC, RBC, HGB, HCT,MCV,MCH,MCHC,RDW,RDW-SD, PLT, MPV</td><td rowspan=1 colspan=1>Whole Blood</td><td rowspan=1 colspan=1>•   Automated Cassette Closed Vial•   Manual Single Tube Closed Vial•   Manual Single Tube Open Vial</td></tr><tr><td rowspan=1 colspan=1>CBC andDifferentialinc NRBC(CD)</td><td rowspan=1 colspan=1>•   WBC, RBC, HGB, HCT,MCV, MCH, MCHC,RDW,RDW-SD, PLT, MPV,4   NE%, NE#, LY%, LY#, MO%,MO#, EO%, EO#, BA%, BA#,NRBC% and NRBC#.</td><td rowspan=1 colspan=1>Whole Blood</td><td rowspan=1 colspan=1>•   Automated Cassette Closed Vial•  Manual Single Tube Closed Vial&quot;   Manual Single Tube Open Vial</td></tr><tr><td rowspan=1 colspan=1>CBC,Differentialinc NRBCand Retic(CDR)</td><td rowspan=1 colspan=1>•   WBC, RBC,HGB, HCT,MCV, MCH, MCHC,RDW,RDW-SD, PLT, MPV,   NE%, NE#, LY%, LY#, MO%,MO#, EO%, EO#, BA%, BA#,NRBC%, NRBC#,RET%, RET#, MRV, IRF</td><td rowspan=1 colspan=1>Whole Blood</td><td rowspan=1 colspan=1>•   Automated Cassette Closed Vial•   Manual Single Tube Closed Vial•   Manual Single Tube Open Vial</td></tr><tr><td rowspan=1 colspan=1>CBC andRetic(CR)</td><td rowspan=1 colspan=1>WBC, RBC, HGB, HCT,MCV, MCH, MCHC,RDW,RDW-SD, PLT, MPV,RET%, RET#, MRV, IRF</td><td rowspan=1 colspan=1>Whole Blood</td><td rowspan=1 colspan=1>Automated Cassette Closed VialManual Single Tube Closed Vial   Manual Single Tube Open Vial</td></tr><tr><td rowspan=1 colspan=1>Retic(R)</td><td rowspan=1 colspan=1>RET% RET#, MRV, IRF</td><td rowspan=1 colspan=1>Whole Blood</td><td rowspan=1 colspan=1>•   Automated Cassette Closed Vial•  Manual Single Tube Closed Vial•  Manual Single Tube Open Vial</td></tr><tr><td rowspan=1 colspan=1>Pre-dilute(PreDilx5)</td><td rowspan=1 colspan=1>•   WBC, RBC, HGB, HCT,MCV, MCH, MCHC, RDW,RDW-SD, PLT, MPV</td><td rowspan=1 colspan=1>1 in 5 Pre-diluted wholeblood</td><td rowspan=1 colspan=1>Manual Single Tube Open Vial</td></tr><tr><td rowspan=1 colspan=1>Body Fluid(BF)</td><td rowspan=1 colspan=1>•   TNC, RBC</td><td rowspan=1 colspan=1>Body Fluid(cerebrospinal,serous andsynovial</td><td rowspan=1 colspan=1>   Manual Single Tube Open Vial</td></tr></table>

Table 5: DxH 800 test panels, reported parameters and sampling methods

# Test Principle

The Coulter Principle of automated cell counting and sizing is used in the analysis of the whole blood and body fluid specimens.

Each cell suspended in a conductive liquid (diluent) acts as an insulator. As each cell goes through the aperture, it momentarily increases the resistance of the electrical path between two submerged electrodes on either side of the aperture. This causes a measurable electronic pulse. While the number of pulses indicates particle count, the amplitude of the electrical pulse is proportional to the cell volume. These pulses are sent to the Signal Conditioner for analog to digital conversion. Pulse counts and digitized pulse measurements are sent to the System Manager for processing by the algorithms where the reported parameter values, flags and histograms are generated.

# UniCel® DxH 800 COULTER® Cellular Analysis System Update $5 [ 0 ( k )$ submission Section 5: 510(k) Summary - Updated

The lytic reagent used for the white cell count prepares the blood so the system can count leukocytes and measure the amount of hemoglobin. The lytic reagent rapidly and simultaneously destroys the erythrocytes and converts a substantial proportion of the hemoglobin to a stable pigment while it leaves leukocyte nuclei intact. The absorbance of the pigment is directly proportional to the hemoglobin concentration of the sample.

Hemoglobin is measured photometrically at $5 2 5 ~ \mathrm { { n m } }$ using the sample from the white cell analysis. Clean diluent is introduced into the cuvette during each operating cycle and is used as a blank in the calculation of the HGB.

The COULTER $\mathfrak { B }$ VCSn technology is used to determine the white cell differential, nucleated red blood cell count and reticulocyte parameters along with associated flags, messages, histograms and dataplots.

The sample preparation and analysis uses specific reagents and analytical processes for the WBC differential, NRBC and Retic analysis. The prepared sample is delivered to the flow cell for sample detection. As the cells pass through the sensing zone, a diode laser illuminates the particles causing light scatter and light absorption. Simultaneously to the light scatter measurements, cell volume and cell conductivity are also measured.

The data collected during each of the analytical processes is transferred to the System Manager where the digital raw values are processed by the algorithm using mathematical approaches designed for finding optimal separation between clusters of data. The identified clusters are used to calculate the frequency of cells within each population, generate parameter values, flags, histograms and data plots.

# 6.0 Intended Use:

The $\mathrm { U n i C e l ^ { \otimes } D x H 8 0 0 C O U L T E R ^ { \otimes } }$ Analyzer is a quantitative multi-parameter, automated hematology analyzer for in vitro diagnostic use in screening patient populations found in clinical laboratories.

The UniCel® DxH 800 COULTER® Analyzer identifies and enumerates the parameters indicated below on the following sample types:

Whole Blood (Venous and Capillary) WBC, RBC, HGB, HCT, MCV, MCH, MCHC, RDW, RDW-SD, PLT, MPV, $N E \%$ , NE#, $\mathrm { L Y \% }$ ,LY#, $M O \%$ , MO#, $\mathrm { E O \% }$ , EO#, $B A \%$ , BA#, NRBC%, NRBC#, RET%, RET#, MRV, IRF   
Pre-Diluted Whole Blood (Venous and Capillary) O WBC, RBC, HGB, HCT, MCV, MCH, MCHC, RDW, RDW-SD, PLT, MPV   
Body Fluids (cerebrospinal, serous and synovial) TNC and RBC

# Indication for Use.

See Intended Use above.

UniCel® DxH 800 COULTER® Cellular Analysis System Update   
510(k) submission   
Section 5: 510(k) Summary - Updated

0L   

<table><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>UniCel® DxH800Predicate</td><td rowspan=1 colspan=1>UniCel® DxH800 UpdateTest Device(Software 2.0)</td></tr><tr><td rowspan=1 colspan=1>Intended Use and Function</td><td rowspan=1 colspan=1>The UniCel® DxH 800 Analyzer is a quantitative,automated hematology analyzer for in vitro diagnosticuse in screening patient populations found in clinicallaboratories.The UniCel® DxH 800 Analyzer provides a:Complete Blood Count (CBC), Leukocyte 5 PartDifferential (Diff), Reticulocyte (Retic) andNucleated Red Blood Cell (NRBC) on wholebloodTotal Nucleated Count (TNC) and Red Cell Count(RBC) on Body Fluids (cerebrospinal, serous andsynovial) (BF)</td><td rowspan=1 colspan=1>The Indications for Use for the updated DxH 800 have notchanged. The statement has been reworded to provideclarity and specific information on the parameters reportedfrom each of the specimen types that are analyzed on thedevice.The UniCel® DxH 800 Analyzer is a quantitative multi-parameter, automated hematology analyzer for in vitrodiagnostic use in screening patient populations found inclinical laboratories.The UniCel® DxH 800 Analyzer identifies and enumerates theparameters indicated below on the following sample types:Whole Blood (Venous and Capillary)WBC, RBC, HGB, HCT, MCV, MCH,MCHC, RDW, RDW-SD, PLT, MPV, NE%,NE#, LY%, LY#, MO%, MO#, EO%, EO#,BA%, BA#, NRBC%, NRBC#, RET%,RET#, MRV, IRFPre-Diluted Whole Blood (Venous and Capillary)WBC, RBC, HGB, HCT, MCV, MCH,MCHC, RDW, RDW-SD, PLT, MPVBody Fluids (cerebrospinal, serous and synovial)TNC and RBC</td></tr></table>

<table><tr><td rowspan=1 colspan=1>WBC, RBC, MCV, PIt,BF-TNC, BF-RBC</td><td rowspan=1 colspan=1>Aperture impedance (Coulter® Principle)</td><td rowspan=1 colspan=1>Same as predicate DxH 800</td></tr><tr><td rowspan=1 colspan=1>Hgb</td><td rowspan=1 colspan=1>Spectrophotometric</td><td rowspan=1 colspan=1>Same as predicate DxH 800</td></tr><tr><td rowspan=1 colspan=1>WBC Differential,</td><td rowspan=1 colspan=1>VCSn Technology using :Aperture impedance (DC)Conductivity (RF)Laser Light Scatter (Multiple angles)Laser Light Absorbance</td><td rowspan=1 colspan=1>Same as predicate DxH 800</td></tr><tr><td rowspan=1 colspan=1>Retic</td><td rowspan=1 colspan=1>VCSn Technology using :Aperture impedance (DC)Conductivity (RF)Laser Light Scatter (Multiple angles)Laser Light Absorbance</td><td rowspan=1 colspan=1>Same as predicate DxH 800</td></tr><tr><td rowspan=1 colspan=1>NRBC</td><td rowspan=1 colspan=1>VCSn Technology using :Aperture impedance (DC)Conductivity (RF)Laser Light Scatter (Multiple angles)Laser Light Absorbance</td><td rowspan=1 colspan=1>Same as predicate DxH 800</td></tr><tr><td rowspan=1 colspan=3>Reagents</td></tr><tr><td rowspan=1 colspan=1>Analysis Reagents</td><td rowspan=1 colspan=1>COULTER® DxH DiluentCOULTER® DxH Diff PackCOULTER® DxH Retic PackCOULTER DxH Cell Lyse</td><td rowspan=1 colspan=1>Same as predicate DxH 800</td></tr><tr><td rowspan=1 colspan=1>Quality Controls &amp;Calibrator</td><td rowspan=1 colspan=1>COULTER® 6C Cell ControlCOULTER® Latron™M CP-X ControlCOULTER® RETIC-X Cell ControlCOULTER@ LIN-X ControlCOULTER@ Body Fluids ControlCOULTER® S-CAL Calibrator kit</td><td rowspan=1 colspan=1>Same as predicate DxH 800</td></tr><tr><td rowspan=1 colspan=1>Cleaning Agent</td><td rowspan=1 colspan=1>COULTER® DxH Cleaner</td><td rowspan=1 colspan=1>Same as predicate DxH 800</td></tr></table>

<table><tr><td rowspan="2">System configuration Sampling Mechanism</td><td>Bench top or Optional Floor Stand - provides self-contained support for the analyzer as well as easy access storage for reagents and waste containers. PC based workstation running Microsoft Windows XP application specific software</td><td>Same as predicate DxH 800</td></tr><tr><td>Handheld Barcode Scanner Printer Single tube presentation - open and closed vial sampling Automated presentation - closed vial sampling from 5</td><td>Same as predicate DxH 800 with:</td></tr><tr><td>Mechanisms for processing</td><td>position cassette. Maximum initial load capacity 20 racks Mechanisms to achieve process of : automated cassette transportation and specimen mixing (by rocking), sample aspiration, sample preparation, sample and reagent presentation to analytical modules, sample analysis, raw data collection, algorithmic processing and data reporting</td><td>Updates to provide dedicated cassette and mixing profile for specific tubes. Same as predicate DxH 800 with: Updates for device reliability, manufacturability and serviceability.</td></tr><tr><td rowspan="2">Sample identification</td><td>directional moves and capability to return cassette to sampling position for repeat / reflex testing. Sample aspiration module (SAM) mounted barcode reader for automated barcode reading of cassette and sample tube identifiers</td><td>Same as predicate DxH 800 with:</td></tr><tr><td>Manual barcode scanning of sample tube identifier (Handheld scanner) Manual keyboard entry of sample identifier</td><td>Corrections to address sample identification related recalls. Updates to add capability for host query</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Aspiration Pathway</td><td rowspan=1 colspan=1>Single sampling probe and common aspiration pathway usedfor all sample presentation modes.</td><td rowspan=1 colspan=1>Same as predicate DxH 800</td></tr><tr><td rowspan=1 colspan=1>Sample aspirationvolume</td><td rowspan=1 colspan=1>Automatic, cap-piercing : 165 μLSingle tube - open-vial and cap pierce: 165 µLPredilute 165 µL - fixed ratio of 1 in 5 dilution of blood withdiluent</td><td rowspan=1 colspan=1>Same as predicate DxH 800</td></tr><tr><td rowspan=1 colspan=1>Sample Preparation</td><td rowspan=1 colspan=1>Rotary blood sampling valve (BSV) and syringe aspiration /dispense for blood segmentation / distributionRotary ceramic piston pumps driven by stepper motors forreagent deliveryCBC dilutions mixed vial tangential delivery to bathsVCSn dilutions mixed by air jet in reaction chambersReagents are temperature stabilized for analysis reactions</td><td rowspan=1 colspan=1>Same as predicate DxH 800</td></tr><tr><td rowspan=1 colspan=1>Throughput :Automated cassetteprocessing</td><td rowspan=1 colspan=1>CBC ≥100 specimens per hourCBC/Diff ≥100 specimens per hourCBC/Diff/NRBC ≥ 90 specimens per hourAny cycle with Retic ≥45 specimens per hourThroughput is based on normal specimens — analytical cycletimes are increased with cytopenic specimens.</td><td rowspan=1 colspan=1>Same as predicate DxH 800</td></tr><tr><td rowspan=1 colspan=1>Data Analysis</td><td rowspan=1 colspan=1>Raw information is digitized from all analytical modules andpassed to workstation for algorithmic processing.Algorithms using advanced mathematical methods forpopulation differentiation and flagging centralized withinworkstation</td><td rowspan=1 colspan=1>Same as Predicate DxH 800 with:Enhancements for improved flagging</td></tr><tr><td rowspan=1 colspan=1>Data reporting</td><td rowspan=1 colspan=1>Workstation display graphics, hardcopy printing andtransmission to Laboratory Information System (LIS)</td><td rowspan=1 colspan=1>Same as Predicate DxH 800 with:Corrections to address data reporting related recalls.Updates to include revised LIS communicationprotocol to improve software performance andadditional printer support functions.</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Controlling software</td><td rowspan=1 colspan=1>System software (embedded and workstation) designedspecific to support all features of DxH 800The software system consists of a Data Managercomponent, a System Manager component (includingalgorithms), the User Interface, all of which areresident in the Workstation. In addition an EmbeddedApplication is resident in the analyzer. The Embeddedapplication uploads from the workstation on systempower-up.Extensive real time monitoring and reporting of systemstatus including:Component and module activities,System Voltages and CurrentsSystem Pressure and VacuumSystem TemperaturesMotor activityMechanism Sensor statusReagent Pump OperationRaw data collection</td><td rowspan=1 colspan=1>Same as DxH 800 predicate with:Corrections to address software related recalls.Updates to improve removal of cleaning agent duringShutdown and Daily Checks and monitoring ofSample and Sheath pressure sensors reading to detectwhen sensors are disconnectedSoftware architecture changes that provide afoundation for future product enhancements andplatform expansion.</td></tr><tr><td rowspan=1 colspan=3>Performance</td></tr><tr><td rowspan=1 colspan=1>Performance Claims</td><td rowspan=1 colspan=1>As stated in the Instructions for Use for the predicatedevice.</td><td rowspan=1 colspan=1>Performance claims are the same as the predicate DxH800 with the following updates based on alignment tocurrent clinical testing standardsUpdated Operating and Measuring ranges forselected parametersTo align selected parameter lowerlimits with background, Limit of Blank,Limit of Detection and Limit ofQuantitation.0  To align selected upper parameterlimits with values seen in clinicalconditions.Updated NRBC Carryover specification</td></tr></table>

r   e 8   
Ue c  e    e   

<table><tr><td rowspan=1 colspan=1>Study</td><td rowspan=1 colspan=1>Testing Approach</td><td rowspan=1 colspan=1>FDA GuidanceDocuments</td><td rowspan=1 colspan=1>Standards / References</td><td rowspan=1 colspan=1>510(k) Testing Summary</td></tr><tr><td rowspan=1 colspan=1>Accuracy-ComparabilityWhole blood andBody fluid</td><td rowspan=1 colspan=1>Whole blood and Body Fluidaccuracy (comparability)testing was performed todemonstrate the updated DxH800 meets accuracy claims(Bias and/or Difference) limitsover the measuring rangesdefined in product labeling.</td><td rowspan=1 colspan=1>Class II SpecialControls GuidanceSection 8 - Accuracy</td><td rowspan=1 colspan=1>Standards Documents•   Validation, Verification, and QualityAssurance of Automated HematologyAnalyzers, Approved Standard - 2ndEdition; June 2010; CLSI H26-A2(FDA Standards Recognition # 7-210)Method Comparison and BiasEstimation Using Patient Samples;CLSI EP9-A2 (FDA StandardsRecognition # 7-92)Reference Leukocyte (WBC)Differential Count (Proportional) andEvaluation of Instrumental Methods;CLSI H20-A2 (FDA StandardsRecognition # 7-165)Body Fluid Analysis for CellularComposition; CLSI H56-A(FDA Standards Recognition # 7-163)</td><td rowspan=1 colspan=1>Analysis of the data collecteddemonstrates that the updated DxH800 meets the performancerequirements and provides resultswithin acceptance limits forparameters reported from wholeblood, when compared to thepredicate device and fordifferential parameters whencompared to manual referenceresults. In addition the updatedDxH 800 meets the performancerequirements and provides resultswithin acceptance limits forparameters reported from bodyfluid, when compared to themanual chamber count.</td></tr><tr><td rowspan=1 colspan=1>Accuracy-ComparabilityAnalytical cycles</td><td rowspan=1 colspan=1>Testing was performed on theupdated DxH 800 todemonstrate equivalency ofresults (within defined limits)between the whole bloodanalytical cycles (test panels),CBC (C), CBC/DIFF (CD),CBC/DIFF/Retic (CDR),CBC/Retic (CR), Retic (R)when specimens are analyzedusing the automated closedvial sample processingmethod. In addition testingwas performed to demonstrateequivalency betweenspecimens analyzed as wholeblood and as Pre-dilute (PD)specimens.</td><td rowspan=1 colspan=1>Class II SpecialControls GuidanceSection 8 - Accuracy</td><td rowspan=1 colspan=1>Standards DocumentsValidation, Verification, and QualityAssurance of Automated HematologyAnalyzers, Approved Standard - 2ndEdition; June 2010; CLSI H26-A2(FDA Standards Recognition # 7-210)User Verification of Performance forPrecision and Trueness ApprovedGuideline; Approved Guideline -Second Edition; June 2005; CLSIEP15-A2(FDA Standards Recognition # 7-153)</td><td rowspan=1 colspan=1>Analysis of the data collecteddemonstrates that the updated DxH800 meets the performancerequirements and providescomparable results for allparameters reported fromspecimens analyzed as whole bloodin the available analytical cyclesand when analyzed as whole bloodand pre-dilute samples.</td></tr></table>

<table><tr><td colspan="1" rowspan="1">Study</td><td colspan="1" rowspan="1">Testing Approach</td><td colspan="1" rowspan="1">FDA GuidanceDocuments</td><td colspan="1" rowspan="1">Standards / References</td><td colspan="1" rowspan="1">510(k) Testing Summary</td></tr><tr><td colspan="1" rowspan="1">Accuracy -ComparabilitySampling modes</td><td colspan="1" rowspan="1">Testing was performed todemonstrate comparabilitybetween the sampling modesavailable on the updated DxH800. Testing compared theautomated closed vial with themanual closed vial samplingand the manual closed vialwith the manual open vialmethods using the CBC,Differential and Reticanalytical cycle.</td><td colspan="1" rowspan="1">Class II SpecialControls GuidanceSection 8 - Accuracy</td><td colspan="1" rowspan="1">Standards DocumentsValidation, Verification, and QualityAssurance of Automated HematologyAnalyzers, Approved Standard - 2ndEdition; June 2010; CLSI H26-A2( FDA Standards Recognition # 7-210)User Verification of Performance forPrecision and Trueness ApprovedGuideline; Approved Guideline -Second Edition; June 2005; CLSIEP15-A2(FDA Standards Recognition # 7-153)</td><td colspan="1" rowspan="1">Analysis of the data collecteddemonstrates that the updated DxH800 meets performancerequirements to providecomparable results for allparameters reported, for specimensanalyzed using the samplingmethods available (automatedclosed vial, manual closed vial andmanual single tube open vial).</td></tr><tr><td colspan="1" rowspan="1">Reproducibility</td><td colspan="1" rowspan="1">Testing was performed on theupdated DxH 800 todemonstrate the long termimprecision of the device.Testing was performed usingmultiple levels of controlmaterials for CBC,Differential, NRBC, Retic andBody Fluid parameters.</td><td colspan="1" rowspan="1">Class II SpecialControls GuidanceSection 9 - Precision</td><td colspan="1" rowspan="1">Standards DocumentsValidation, Verification, and QualityAssurance of Automated HematologyAnalyzers, Approved Standard - 2ndEdition; June 2010; CLSI H26-A2(FDA Standards Recognition # 7-210)Evaluation of Precision Performance ofQuantitative Measurement Methods;Approved Guideline - Second edition;August 2004. CLSI EP05-A2(FDA Standards Recognition # 7-110)</td><td colspan="1" rowspan="1">Analysis of the data collecteddemonstrates that the updated DxH800 meets the performancerequirements (within acceptancelimits) for reproducibility (longterm imprecision) using controlproducts.</td></tr><tr><td colspan="1" rowspan="1">Repeatability</td><td colspan="1" rowspan="1">Testing was performed on theupdated DxH 800 todemonstrate the short termimprecision of the device.Testing was performed usingreplicate measurements ofspecimens in the normalrange, at medical decisionlevels and over the analyticalmeasuring interval. Testingwas performed on wholeblood, pre-diluted whole bloodand body fluid specimens</td><td colspan="1" rowspan="1">Class II SpecialControls GuidanceSection 9 - Precision</td><td colspan="1" rowspan="1">Standards DocumentsValidation, Verification, and QualityAssurance of Automated HematologyAnalyzers, Approved Standard - 2ndEdition; June 2010; CLSI H26-A2(FDA Standards Recognition # 7-210)Evaluation of Precision Performance ofQuantitative Measurement Methods;Approved Guideline — Second edition;August 2004. CLSI EP05-A2(FDA Standards Recognition # 7-1 10)Body Fluid Analysis for CellularComposition; Approved Guideline,June 2006. CLSI H56-A(FDA Standards Recognition # 7-163)Reference DocumentsHubl, W.; Tlustos, L.and M. Bayer,Use of precision profiles to evaluateprecision of the automated leukocytedifferential. Clinical Chemistry 42:7,1068, 1996.</td><td colspan="1" rowspan="1">Analysis of the data collecteddemonstrates that the updated DxH800 meets performancerequirements for repeatability,(within acceptance limits) for allparameters reported.</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Study</td><td rowspan=1 colspan=1>Testing Approach</td><td rowspan=1 colspan=1>FDA GuidanceDocuments</td><td rowspan=1 colspan=1>Standards / References</td><td rowspan=1 colspan=1>510(k) Testing Summary</td></tr><tr><td rowspan=1 colspan=1>PerformanceLoB. LLoD,LLoQ</td><td rowspan=1 colspan=1>Limit of Blank, Lower Limitof Detection and Lower Limitof Quantitation testing wasperformed for the parameterswhere there is a clinicalinterest (medical decisionlevel) on very low or near zerovalues.Whole bloodWBC and PLTBody FluidTNC and RBC</td><td rowspan=1 colspan=1>Class II SpecialControls GuidanceSection 10 -Performance</td><td rowspan=1 colspan=1>Standards DocumentsValidation, Verification, and QualityAssurance of Automated HematologyAnalyzers, Approved Standard - 2ndEdition; June 2010; CLSI H26-A2(FDA Standards Recognition # 7-210)Protocols for Determination of Limitsof Detection and Limits ofQuantitation; CLSI EP17-A(FDA Standards Recognition # 7-194)</td><td rowspan=1 colspan=1>Analysis of the data collecteddemonstrates that the updated DxH800 meets the performancerequirements for LoB, LLoD andLLoQ results (within acceptancelimits), for the WBC and PLTparameters in whole blood and theBF-TNC and BF-RBC parametersin body fluids.</td></tr><tr><td rowspan=1 colspan=1>PerformanceClinicalSensitivity andSpecificity</td><td rowspan=1 colspan=1>Clinical Sensitivity andSpecificity are used to assessthe ability of a test to detectpresence or absence of acondition/abnormality. For theupdated DxH 800, ClinicalSensitivity and Specificity wasused to assess the WBCDifferential Suspect messageflagging capability of thesystem.</td><td rowspan=1 colspan=1>Class II SpecialControls GuidanceSection 10 -Performance</td><td rowspan=1 colspan=1>Standards DocumentsValidation, Verification, and QualityAssurance of Automated HematologyAnalyzers, Approved Standard - 2ndEdition; June 2010; CLSI H26-A2(FDA Standards Recognition # 7-210)Reference Leukocyte (WBC)Differential Count (Proportional) andEvaluation of Instrumental Methods;CLSI H20-A2(FDA Standards Recognition # 7-165)Reference DocumentsThe International Consensus Group forHematology Review: SuggestedCriteria for Action FollowingAutomated CBC and WBC DifferentialAnalysis; Laboratory Hematology,11:83-90, 2005</td><td rowspan=1 colspan=1>Analysis of the data collecteddemonstrates that the updated DxH800 provided equivalent orimproved performance for ClinicalSensitivity and Specificity ascompared to the predicate deviceanalyzing the same data set.</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Study</td><td rowspan=1 colspan=1>Testing Approach</td><td rowspan=1 colspan=1>FDA GuidanceDocuments</td><td rowspan=1 colspan=1>Standards / References</td><td rowspan=1 colspan=1>510(k) Testing Summary</td></tr><tr><td rowspan=1 colspan=1>LinearityWhole blood andBody fluid</td><td rowspan=1 colspan=1>Testing was performed on theupdated DxH 800 todemonstrate the linearity ofthe device. Linearity wasassessed by demonstrating thatthe reported results aredirectly proportional to theconcentration of themeasurand in a test sample forwhole blood and body fluids.</td><td rowspan=1 colspan=1>Class II SpecialControls GuidanceSection 11 - Linearity</td><td rowspan=1 colspan=1>Standards DocumentsValidation, Verification, and QualityAssurance of Automated HematologyAnalyzers, Approved Standard - 2ndEdition; June 2010; CLSI H26-A2(FDA Standards Recognition # 7-210)Evaluation of the Linearity ofQuantitative Measurement; ApprovedGuideline; April 2003. CLSI EP06-A(FDA Standards Recognition # 7-193)</td><td rowspan=1 colspan=1>Analysis of the data collecteddemonstrates that the updated DxH800 meets the performancerequirements and provides linearresults, within acceptance limits,for Whole blood and Body Fluid.</td></tr><tr><td rowspan=1 colspan=1>CarryoverWhole blood andBody fluid</td><td rowspan=1 colspan=1>Testing was performed todemonstrate whole blood andbody fluid carryoverperformance of the updatedDxH 800 by determining theimpact of a specimen havinghigh parameter valuespreceding a specimen withlow parameter values. Thistesting also serves substantiatethe modified NRBC carryoverclaim for the updated DxH800.</td><td rowspan=1 colspan=1>Class II SpecialControls GuidanceSection 12 -Carryover</td><td rowspan=1 colspan=1>Standards DocumentsValidation, Verification, and QualityAssurance of Automated HematologyAnalyzers, Approved Standard - 2ndEdition; June 2010; CLSI H26-A2(FDA Standards Recognition # 7-210)Reference DocumentsGuidelines for the evaluation of bloodcell analyzers including those used fordifferential leukocyte and reticulocytecounting and cell marker applications.International Council forStandardization in Haematology:prepared by the ICSH expert panel oncytometry. Clin Lab Haematol,16(2):157-174, 1994.</td><td rowspan=1 colspan=1>Analysis of the data collecteddemonstrates that the updated DxH800 meets the whole blood andbody fluid carryover performancerequirements (within acceptancelimits), for the parametersmeasured.</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Study</td><td rowspan=1 colspan=1>Testing Approach</td><td rowspan=1 colspan=1>FDA GuidanceDocuments</td><td rowspan=1 colspan=1>Standards / References</td><td rowspan=1 colspan=1>510(k) Testing Summary</td></tr><tr><td rowspan=1 colspan=1>SpecimensAnticoagulant</td><td rowspan=1 colspan=1>Testing was performed on theupdated DxH 800 todemonstrate equivalency ofresults for whole bloodspecimens collected into K2and KEDTA and analyzedusing the CBC, Differentialand Retic analytical cycle.</td><td rowspan=1 colspan=1>Class II SpecialControls GuidanceSection 13 -Specimens</td><td rowspan=1 colspan=1>Standards DocumentsValidation, Verification, and QualityAssurance of Automated HematologyAnalyzers, Approved Standard - 2ndEdition; June 2010; CLSI H26-A2(FDA Standards Recognition # 7-210)Procedures for the Collection ofDiagnostic Blood Specimens byVenipuncture; Approved Standard -Sixth Edition; October 2007; CLSI H3-A6(FDA Standards Recognition # 7-201)Procedures and Devices for theCollection of Diagnostic CapillaryBlood Specimens; Approved Standard -Sixth Edition; September 2008; CLSIH04-A6(FDA Standards Recognition # 7-203)User Verification of Performance forPrecision and Trueness ApprovedGuideline; Approved Guideline -Second Edition; June 2005; CLSIEP15-A2(FDA Standards Recognition # 7-153)Reference DocumentsRecommendations of the InternationalCouncil for Standardization inHaematology forethylenediaminetetraacetic acidanticoagulation of blood for blood cellcounting and sizing. Am J Clin Path,100(4)371-372, 1993.</td><td rowspan=1 colspan=1>Analysis of the data collecteddemonstrates that the updated DxH800 meets performancerequirements and providescomparable results, for allparameters reported, fromspecimens collected into K2 andKEDTA.</td></tr></table>

Uu       e   

<table><tr><td rowspan=1 colspan=1>Study</td><td rowspan=1 colspan=1>Testing Approach</td><td rowspan=1 colspan=1>FDA GuidanceDocuments</td><td rowspan=1 colspan=1>Standards / References</td><td rowspan=1 colspan=1>510(k) Testing Summary</td></tr><tr><td rowspan=1 colspan=1>SpecimensCollectionmethod</td><td rowspan=1 colspan=1>Testing was performedon the updated DxH800 to demonstrateequivalency of results(within defined limits),for specimens collectedby venipuncture andcapillary collectionmethods and analyzedusing the CBC,Differential and Reticanalytical cycle.</td><td rowspan=1 colspan=1>Class II Special ControlsGuidanceSection 13 - Specimens</td><td rowspan=1 colspan=1>Standards Documents.  Validation, Verification, and QualityAssurance of Automated HematologyAnalyzers, Approved Standard - 2ndEdition; June 2010; CLSI H26-A2(FDA Standards Recognition # 7-210)Procedures for the Collection ofDiagnostic Blood Specimens byVenipuncture; Approved Standard - SixthEdition; October 2007; CLSI H3-A6(FDA Standards Recognition # 7-201)Procedures and Devices for the Collectionof Diagnostic Capillary BloodSpecimens; Approved Standard - SixthEdition; September 2008; CLSI H04-A6(FDA Standards Recognition # 7-203)User Verification of Performance forPrecision and Trueness ApprovedGuideline; Approved Guideline - SecondEdition; June 2005; CLSI EP15-A2(FDA Standards Recognition # 7-153)</td><td rowspan=1 colspan=1>Analysis of the data collecteddemonstrates that the updated DxH800 meets the performancerequirements and providescomparable results, for allparameters reported fromspecimens collected byvenipuncture and capillarycollection methods and analyzedusing the CBC, Differential andReticulocyte analytical cycle.</td></tr><tr><td rowspan=1 colspan=1>SpecimensStability</td><td rowspan=1 colspan=1>Testing was performedon the updated DxH800 to demonstratewhole blood specimenstability. Testing wasperformed on wholeblood specimens atvarious time intervals(long-term and short-term) and stored atrefrigerated and roomtemperature. In additiontesting was performedon pre-dilutedspecimens.</td><td rowspan=1 colspan=1>Class II Special ControlsGuidanceSection 13 - Specimens</td><td rowspan=1 colspan=1>Standards DocumentsNone</td><td rowspan=1 colspan=1>Analysis of the data collecteddemonstrates that the updated DxH800 meets the performancerequirements and claims withrespect to whole blood long term,short term and pre-dilute samplestability.</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Study</td><td rowspan=1 colspan=1>Testing Approach</td><td rowspan=1 colspan=1>FDA GuidanceDocuments</td><td rowspan=1 colspan=1>Standards / References</td><td rowspan=1 colspan=1>510(k) Testing Summary</td></tr><tr><td rowspan=1 colspan=1>ReferenceRanges</td><td rowspan=1 colspan=1>Confirmatory testingwas performed on theupdated DxH 800 todemonstratecomparability of wholeblood reference rangesfor an adult populationto the rangesestablished for thepredicate device.</td><td rowspan=1 colspan=1>Class II Special ControlsGuidanceSection 14 - ReferenceValues</td><td rowspan=1 colspan=1>Standards Documents•  Defining, Establishing, and VerifingReference Intervals in the ClinicalLaboratory; Approved Guideline - ThirdEdition. CLSI C28-A3(FDA Standards Recognition # 7-202)</td><td rowspan=1 colspan=1>The reference ranges establishedfor the predicate DxH 800 areapplicable for the updated DxH800. The updated DxH 800labeling will provide the referenceranges as currently presented in thepredicate labeling.</td></tr></table>

The data in the Premarket Notification on safety and effectiveness supports a finding that the $\mathrm { U n i C e l ^ { \mathfrak { P } } D x H 8 0 0 C O U L T E R ^ { \mathfrak { G } } }$ Cellular Analysis System Update with software version 2.0 is substantially equivalent to the predicate device.

This summary of safety and effectiveness is being submitted in accordance with the requirements of the Safe Medical Device Act of 1990 and the implementing regulation 21 CFR 807.92.

# UniCel® DxH 800 COULTER® Cellular Analysis System Update $5 1 0 ( \mathbf { k } )$ submission Section 5: 510(k) Summary - Updated

Beckman Coulter, Inc. c/o Mr. Eric Grace Senior Staff, Product Management 11800 SW $1 4 7 ^ { \mathrm { t h } }$ Avenue Miami, Florida 33196-2500

Re: k120771 Trade/Device Name: UniCel® DxH 800 COULTER $\mathfrak { P }$ Cellular Analysis System Regulation Number: 21 CFR $\ S 8 6 4 . 5 2 2 0$ Regulation Name: Automated differential cell counter Regulatory Class: Class II Product Code: GKZ Dated: March 11, 2013 Received: March 14, 2013

Dear Mr. Grace:

We have reviewed your Section 5 10(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note:CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class II (PMA), it ay b subject to additnal controls.Existing major regulations affecting your device can be fud inhe odef Federal Regulations, Tite, Parts 800 to In addition, Fmy publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

# Maria M. Chan -S

Maria M. Chan, Ph.D.   
Director   
Division of Immunology and Hematology Devices Office of In Vitro Diagnostics and Radiological Health   
Center for Devices and Radiological Health

# Indication for Use

# 510(k) Number (if known): K120771

Devic Name: UniCel®DxH 800 COULTER® Cellular Analysis System

# Indication for Use:

The UniCel® DxH 800 Analyzer is a quantitative multi-parameter, automated hematology analyzer for in vitro diagnostic use in screening patient populations found in clinical laboratories.

The UniCel® DxH 800 Analyzer identifies and enumerates the parameters indicated below on the following sample types:

Whole Blood (Venous and Capillary) 0 WBC, RBC, HGB, HCT, MCV, MCH, MCHC, RDW, RDW-SD, PLT, MPV, ${ \bf N E \% }$ , NE#, $L Y \%$ ,LY#, $M O \%$ , MO#, $\mathbf { E O \% }$ EO#, $\mathbf { B A } \%$ , BA#, NRBC%, NRBC#, RET%, RET#, MRV, IRF Pre-Diluted Whole Blood (Venous and Capillary) 0 WBC, RBC, HGB, HCT, MCV, MCH, MCHC, RDW, RDW-SD, PLT, MPV Body Fluids (cerebrospinal, serous and synovial) $\circ$ TNC and RBC